Home›Trial›NCT03045029
NCT03045029ACTIVE NOT RECRUITING

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Study Summary

This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation

Conditions
Pulmonary Arterial Hypertension
Interventions / Drugs
Oral treprostinil
View on ClinicalTrials.gov ↗
Sponsor
UTHR
United Therapeutics
Pulmonary
D35/100
Study Details
Enrollment300 participants
Primary Completion—
Lead SponsorUnited Therapeutics
Data Retrieved2026-04-11 04:30:42.432859+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 300 participants
Sponsor Catalyst Profile

United Therapeutics (UTHR) is the sponsoring company for this trial. BiotechSign currently grades this company D (35/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

UTHR Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.